Enanta Pharmaceuticals (NASDAQ:ENTA) announced on Wednesday a lawsuit filed in the EU against Pfizer (NYSE:PFE) and some of ...

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Pfizer ( PFE -0.18%) was a hot stock during the pandemic, but it has been crashing in recent years. The company's COVID ...

In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal ...

Parents won't be able to vaccinate healthy children 6 months to 5 years old if the FDA pulls Pfizer's COVID-19 vaccine ...

Pfizer's experimental drug to treat sickle cell anemia failed to meet the main goal in a late stage trial, the drugmaker said ...

Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...

Several workers reported symptoms of being exposed to a substance and some were taken to the hospital. The state is ...

Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...

Pfizer's Canadian unit and BioNTech said they have received approval in Canada for their updated Comirnaty Covid-19 vaccine. The companies said Monday the updated vaccine targets the Omicron LP.8.1 ...

Chief Executive Albert Bourla says he is hopeful about finding a solution in response to Trump’s demand for price cuts.